Use of protein kinase A activator in the preparation of medicines for the treatment of diseases related to thrombocytopenia

A protein kinase and activator technology, which is applied in the field of protein kinase A activator, the preparation of drugs for treating diseases related to the reduction of platelet count, and achieves the effects of improving PKA activity, protecting platelet apoptosis, and having broad clinical application prospects.

Active Publication Date: 2021-08-06
SUZHOU UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, whether PKA has a greater impact on platelet apoptosis induced by storage or pathological stimuli remains unknown.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of protein kinase A activator in the preparation of medicines for the treatment of diseases related to thrombocytopenia
  • Use of protein kinase A activator in the preparation of medicines for the treatment of diseases related to thrombocytopenia
  • Use of protein kinase A activator in the preparation of medicines for the treatment of diseases related to thrombocytopenia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0045] 1. Reagents and materials:

[0046] Anti-GpIIb / IIIa monoclonal antibody SZ21 was provided by Professor Ruan Changgeng, Director of Jiangsu Institute of Hematology, dimethyl sulfoxide (DMSO) and anti-Actin primary antibody were purchased from Sigma, USA, and EDTA-K2 anticoagulant tubes were purchased from BD, USA Company, fluorescein isothiocyanate (Fluorescein Isothiocyanate, FITC)-Annexin V was purchased from Beijing Jiamei Biotechnology Co., Ltd., FITC-goat anti-mouse antibody was purchased from American Bioworld Technology Company, (Horse Radish Peroxidase, HRP)-goat anti-mouse , HRP-goat anti-rabbit, rabbit and mouse IgG, anti-BAX, anti-BAK, anti-Bcl-xL, anti-Bcl-2, anti-Caspase-3, anti-BAD 155 phosphorylated antibodies were purchased from Santa Cruz Biotechnology Company, USA, anti-PKA Cα antibody was purchased from CST Company, USA, N-[2-((p-Bromocinnamyl)amino)ethyl]-5-isoquinolinesulfonamide (H89), Forsklin, anti-GAPDH, anti-P53 antibody, JC-1, ECL and PMSF wer...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses the use of a protein kinase A activator in the preparation of medicines for treating diseases related to platelet quantity reduction. The present invention explores the role of protein kinase A in the process of regulating platelet apoptosis through experiments for the first time, and finds that the activity of protein kinase A in platelets in patients with thrombocytopenia represented by idiopathic thrombocytopenic purpura, bacterial infection and diabetes decreases Studies have shown that protein kinase A regulates platelet apoptosis by regulating the phosphorylation of BAD 155 serine, and the activation of protein kinase A activity can inhibit the occurrence of endogenous platelet apoptosis. Protein kinase A activators can not only inhibit the occurrence of platelet apoptosis in vitro, but also increase the number of circulating platelets in experimental animals, suggesting that PKA activators can be used in the clinical treatment of thrombocytopenia by inhibiting platelet apoptosis. The potential of forming a new type of platelet protection drug has great scientific research and economic value.

Description

technical field [0001] The invention belongs to the field of platelet-related medicines, and in particular relates to the use of protein kinase A activators in the preparation of medicines for treating diseases related to platelet count reduction. Background technique [0002] Platelets finely regulate blood circulation related thrombus and bleeding balance. At the same time, platelets play an important role in many important pathophysiological processes, such as: immunity, infection, arteriosclerosis, tumor development and metastasis, etc. However, the lifespan of platelets is very short and mysterious, why platelets only circulate in the body for 8-9 days? This problem has plagued mankind for more than half a century. In addition, life-threatening thrombocytopenia often occurs in many high-morbidity diseases, such as diabetes, infection, ITP, and after many pharmacological treatments. The reasons for the shortened platelet lifespan during these pathological processes ar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61K31/522A61K31/5575A61K31/7076A61P7/04A61P7/06A61P7/00
CPCA61K31/522A61K31/5575A61K31/7076A61K45/00
Inventor 戴克胜
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap